Evidence map›Paper›PMID 41964170›Full record

ReviewHuman vaccines & immunotherapeutics2026

The case for an Epstein-Barr virus vaccine: Lessons from its link to systemic lupus erythematosus.

Adewunmi Akingbola, Courage Idahor, Abiodun Adegbesan, Tosin Fakiyesi, Opeyemi Aikulola, Samuel Tundealao, Petra Mariaria

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adewunmi AkingbolaDepartment of Public Health, University of Cambridge, Cambridgeshire, UK.
Courage IdahorDepartment of Emergency Medicine, Henry Ford Providence, Southfield, MI, USA.
Abiodun AdegbesanCancer and Genomics Unit, Menzies Institute for Medical Research, University of Tasmania, Hobert, Australia.
Tosin FakiyesiCollege of Medicine, University of Ibadan, Ibadan, Nigeria.
Opeyemi AikulolaDepartment of Medicine, Lagos State University College of Medicine, Ikeja, Nigeria.
Samuel TundealaoDepartment of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA.
Petra MariariaInfectious Diseases Institute, Makerere University, Kampala, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence has strengthened the longstanding hypothesis that Epstein-Barr virus (EBV) contributes directly to the development of systemic lupus erythematosus (SLE). While earlier work established epidemiologic associations and immune dysregulation in EBV-exposed individuals, recent multi-omic and single-cell studies now demonstrate mechanistic pathways that link viral infection to autoreactive B-cell activation. Notably, EBV has been shown to preferentially infect CD27

Indexed as

Epstein-Barr Virus InfectionsHerpesvirus 4, HumanLupus Erythematosus, SystemicAnimalsB-LymphocytesHumansVirus Latencyautoimmune disease preventionautoreactive B cellsEpstein–Barr virussystemic lupus erythematosusvaccine developmentviral latency

Identifiers

PMID41964170
PMCPMC13078224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.